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Background: Gram-negative bacterial species, such as Actinoba-
cillus actinomycetemcomitans, contain lipopolysaccharide (LPS) that
initiates the innate immune system, resulting in inflammatory alveolar
bone loss. LPS activates Toll-like receptors on membrane surfaces,
stimulating many intracellular signaling cascades, including the p38
mitogen-activated protein kinase (MAPK). Activation of p38 signal-
ing mediates inflammatory cytokine expression, contributing toward
osteoclastogenesis and bone loss. The aim of this study was to deter-
mine whether the novel, orally active p38 MAPK inhibitor SD282 could
arrest progression of LPS-induced alveolar bone destruction in rats.
Methods: Three groups of female Sprague-Dawley rats received
LPS injections to the palatal molar gingiva three times per week for
4 weeks to establish periodontitis. From weeks 5 through 8, two
groups received the drug SD282 (N = 14) or 1% polyethylene glycol
drug vehicle (N = 14) via oral gavage in addition to LPS injections.
The third group continued to receive only LPS injections (N = 8).
Microcomputed tomography was used to measure volumetric alveo-
lar bone loss, expressed as bone volume fraction (BVF). Expression of
interleukin (IL)-1 and -6 and tumor necrosis factor-alpha (TNF-a)
was assessed by immunohistochemistry, and osteoclasts were enu-
merated by tartrate-resistant acid phosphatase staining.
Results: By 4 weeks, severe alveolar bone resorption was seen
in LPS-injected animals. Administration of SD282 significantly blocked
additional volumetric bone loss in the LPS-only versus LPS + SD282
groups (0.37 – 0.01 BVF versus 0.43 – 0.01 BVF; P <0.01). Significant
reductions in IL-1b (P <0.01), TNF-a (P <0.05), and osteoclast formation
(P <0.01) occurred in the presence of SD282.
Conclusions: An orally active p38 MAPK inhibitor reduced LPS-in-
duced inflammatory cytokine expression, osteoclastogenesis, and alve-
olar bone loss in rats. Within the limits of the current study, SD282
arrested periodontal disease progression, thus highlighting the ther-
apeutic potential of this novel class of inhibitors. J Periodontol 2007;
78:1992-1998.
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multiple virulence factors, such
as lipopolysaccharide (LPS), that
can activate the host inflamma-
tory response. An improper or
exuberate immune response leads
to overproduction of inflamma-
tory cytokines and, consequently,
periodontal attachment loss and
alveolar bone loss.1
Within periodontal tissues and
gingival crevicular fluid, activated
monocytes, macrophages, and
fibroblasts produce interleukin
(IL)-1b, IL-6, and tumor necrosis
factor-alpha (TNF-a).2-5 These
cytokines synergistically stim-




LPS increases osteoblastic ex-
pression of IL-1b, TNF-a, prosta-
glandin E2 (PGE2), and receptor
activator of nuclear factor-kappa
B ligand (RANKL), which induces
osteoclast activity, viability, and
differentiation.7,8 Osteoclasts are
activated further in the presence
of A. actinomycetemcomitans by
CD4+ T cells that have an in-
creased expression of RANKL.9,10
Mitogen-activated protein ki-
nases (MAPKs) are intracellular
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kinases required, in part, for inflammation and inflam-
matory bone loss through activation of inflammatory
cytokines and MMPs. LPS binds to its appropriate
membrane receptor (CD14 or Toll-like receptor-4),
and triggers intracellular signaling cascades, inducing
phosphorylation of multiple MAPKs within resident
periodontal cell types. Targeted activation of p38 in-
duced TNF-a and IL-1, -6, and -8 via direct activation
of gene transcription or mRNA stabilization.11-16 p38
MAPK also controls the synthesis of other com-
pounds, including chemokines, metalloproteinases,
prostaglandins, and nuclear factor-kappa B.17 In ad-
dition, our group recently demonstrated that IL-1b–
and TNF-a–induced RANKL expression in bone mar-
row stromal cells requires p38 signaling for maximal
expression, resulting in decreased induction of osteo-
clastogenesis in vitro.16
Therefore, blocking p38 activation could decrease
inflammatory cytokine production and its deleterious
effects. The p38 inhibitors SC409 and SD282 reduced
and reversed bone and cartilage destruction in an
experimental arthritis model.18,19 SD282 also was ca-
pable of preventing alveolar bone loss in a rat peri-
odontitis model.20 The aim of the present study was
to determine whether the orally active p38 inhibitor
SD282 could stop the progression of alveolar bone
loss initiated by A. actinomycetemcomitans LPS in
an experimental rat model.
MATERIALS AND METHODS
Animals
Adult female Sprague-Dawley rats¶ were housed in
pairs under specific pathogen-free conditions with
food and tap water ad libitum. Once weekly, animals
were weighed to ensure proper growth and nutrition.
All protocols were approved by the University Com-
mittee on the Use and Care of Animals, University
of Michigan.
Bone Loss Induction and Administration of
p38 Inhibitor
Within tissue macrophages and other periodontal
cells, MAPKs are activated by A. actinomycetemcomi-
tans LPS.14 Inflammatory bone loss was initiated
according to the aggressive periodontitis model de-
scribed previously.21 LPS was extracted from A. acti-
nomycetemcomitans strain Y4 (serotype B) and
purified, containing <0.001% nucleic acid by spectro-
photometry and 0.7% protein by bicinchoninic acid
protein assay. Three groups of animals received
LPS injections. Using a 33-gauge Hamilton syringe,
2 ml LPS was injected directly into the palatal inter-
proximal gingiva mesial and distal to the second
molar bilaterally. This procedure was repeated three
times each week for 8 weeks. To facilitate LPS injec-
tions, anesthesia was induced with 4% to 5% isoflurane
and maintained with 1% to 2% isoflurane.
The p38 inhibitor SD282 and its vehicle, 1% poly-
ethylene glycol, were administered via oral gavage.
With this technique, liquid compounds can be ad-
ministered directly into the stomach of experimental
animals. A bulb-tipped gastric gavage needle was
passed through the mouth and into the esophagus.
The opposite end of the needle was attached to a sy-
ringe containing the desired substance. This is a sys-
temic administration that ensures the entire volume of
fluid is delivered. All animal handlers received proper
orientation and training in this method prior to initia-
tion of the experiment. Beginning the fifth week, the
test group (N = 14) received twice daily oral gavage
of SD282 (45 mg/kg), whereas the control group
(N = 14) received twice daily oral gavage of drug ve-
hicle. The third group (N = 8) continued to receive LPS
injections only until the end of the experiment. At 8
weeks, all animals were sacrificed by carbon dioxide
asphyxiation. Maxillae were hemisected, and poste-
rior block sections were immersed directly in 10%
buffered formalin fixative solution for ‡72 hours.
Microcomputed Tomography
Non-demineralized rat maxillae were scanned in 70%
ethanol by a cone-beam microcomputed tomography
(mCT) system.# Scans were reconstructed at a mesh
size of 18 mm3 to create a three-dimensional digitized
image of each specimen. Computer software** was
used to analyze the images, set to a threshold of
1,621 and a surface quality factor of 0.5. To create
a standardized orientation, the buccal and palatal
plates were aligned horizontally with the x axis, and
the x plane was made to cross through the palatal
roots.
The amount of bone in each specimen was as-
sessed volumetrically by an independent, masked ex-
aminer, according to methods described recently.20,21
Volumetric changes were assessed within a region
of interest (ROI), the parameters ofwhich were dictated
by the dental anatomy of the specimens. The mesial–
distal width of the ROI was set at the interproximal
height of contour of the molars, whereas the height
of the ROI was equal to the distance from molar cusp
tips to root apices. ROI depth was determined by the
bucco-lingual dimension of the teeth plus 100 voxels
(1.8 mm3). To express the amount of bone present,
the bone volume fraction (BVF) was calculated as fol-
lows: BVF = amount of remaining bone in ROI O ROI.
Immunohistochemistry and Tartrate-Resistant
Acid Phosphatase Staining
Formalin-fixed maxillae were decalcified in 10%
EDTA solution (replenished three times per week)
at 4C for 2 weeks. The maxillae were embedded in
¶ Charles River, Wilmington, MA.
# MicroView 2.1.2, GE Healthcare BioSciences, Chalfont St. Giles, U.K.
** MicroView 2.1.2, GE Healthcare BioSciences.
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paraffin, and 5-mm sections were prepared. Some
specimens from each group were selected for standard
hematoxylin and eosin staining. The remainder was
used for immunohistochemistry. First, deparaffinized
tissue sections were placed in antigen retrieval buf-
fer†† in a pressure chamber‡‡ for 15 minutes. After
cooling the specimens, primary antibodies for anti-
rat IL-6, anti-rat IL-1b, and anti-rat TNF-a monoclo-
nal antibodies were added (1:200 each).§§ Cytokine
presence was detected using reagentii and red stain¶¶
according to the manufacturer’s instructions. Control
sections were incubated with preimmunoserum to
assess background staining level. Photographs of all
prepared sections were taken using an inverted mi-
croscope## and digital camera.***
Cytokine expression was quantified as described
recently.20,21 The overall intensity of red stain on each
slide was judged by three independent, calibrated,
masked examiners. Examiners were calibrated by
comparing digitized images of a known color intensity
to a standardized score sheet showing examples of
each intensity level. Scores of 1 represented <20% pos-
itive stain, 2 represented 21% to 40% positive stain, 3
represented 41% to 60% positive stain, and 4 repre-
sented >60% positive stain. For data collection, slides
were displayed in random order and lacked group
identifying information. Slides were differentiated by
an assigned number, the legend for which was con-
cealed from the examiners.
The presence of osteoclasts was detected by
tartrate-resistant acid phosphatase (TRAP) staining.†††
Active osteoclasts, defined as multinucleated TRAP-
positive cells in contact with the bone surface, were
counted per slide by one examiner at 60· magnifica-
tion. Slides from approximately the same sagittal sec-
tions were used, and slides were identified by assigned
number, as for immunostaining.
Statistical Analysis
The minimum sample size for detecting a difference of
50% between groups was six animals per group.22,23
This was calculated considering a power of 80%. Re-
sults were expressed as means for the entire group.
One maxilla section per animal contributed one mea-
sured value toward the mean for its assigned group.
Statistical comparison was conducted using commer-
cially available software.‡‡‡ Differences among data
were found by one-way analysis of variance, followed
by Bonferroni multiple comparison test. P values
<0.05 were considered statistically significant.
RESULTS
Animals
Three animals were lost in the LPS + vehicle and two in
the LPS + SD282 groups. Although the exact causes of
death were unknown, one explanation could be the
oral gavage technique. Asphyxiation is possible if
the needle is placed incorrectly and liquid is adminis-
tered into the lungs instead of the stomach. Oral ad-
ministration of high doses of SD282 for 8 weeks had
no significant biologic effects in rats.20
SD282 Maintains Alveolar Bone
To evaluate the extent of alveolar bone loss and peri-
odontal destruction, mCT was used as described by
Park et al.24 In the control and experimental groups,
horizontal bone loss with furcation involvement was
evident. This bone loss was most severe between
the molars (Fig. 1), but also was evident at the second
molar palatal furcation.
Volumetric measurements of alveolar bone re-
vealed a significant therapeutic effect from the p38 in-
hibitor (Fig. 2). Continued LPS injections decreased
the BVF between 4 and 8 weeks, from 0.40 – 0.01
to 0.37 – 0.01. However, the administration of SD282
reversed this process and increased the BVF to 0.43 –
0.01. The difference between the 8-week LPS and
8-week LPS with SD282 was significant at P <0.01.
These data strongly suggested that the SD282 ar-
rested further progression of the LPS-induced bone
loss and suggested reversal of LPS-induced bone loss
in this rat model.
SD282 Decreases Inflammatory
Cytokine Expression
Levels of IL-1b and -6 and TNF-a were assessed via
scoring of immunohistochemically stained slides by
calibrated, masked, and independent examiners.
Some slides had to be omitted because of high levels
of background staining that made detection of color
differences difficult. Overall, cytokine levels were de-
creased in the presence of the p38 inhibitor SD282
(Fig. 3). This decrease was significant for IL-1b (P =
0.0019) and TNF-a (P = 0.0193), but approached sig-
nificance for IL-6 (P = 0.0726). For comparison, ani-
mals not injected with LPS showed cytokine levels
<1. This was seen in a similar experiment in which rats
were given SD282 alone by oral gavage.20
SD282 Inhibits Osteoclastogenesis
Osteoclastogenesis, a prerequisite for inflammatory
osteolysis, was measured by the number of TRAP-
positive multinucleated cells per sample (Fig. 4).
There were significantly fewer osteoclasts present in
the LPS + SD282 versus the 8-week LPS groups
(P <0.01). The addition of the p38 inhibitor decreased
†† Dako, Glostrup, Denmark.
‡‡ Biocare Medical, Concord, CA.
§§ R&D Systems, Minneapolis, MN.
ii Vectastain Elite ABC reagent, Vector Labs, Burlingame, CA.
¶¶ Nova Red, Vector Labs.
## Nikon TS100, Nikon, Melville, NY.
*** Nikon CCD 5.1 megapixels, Nikon.
††† Sigma, St. Louis, MO.
‡‡‡ GraphPad Prism Version 4.03, GraphPad Software, San Diego, CA.
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osteoclast levels below baseline (4 weeks of LPS in-
jection).
DISCUSSION
The current study investigated the therapeutic poten-
tial of a novel orally active p38 inhibitor, SD282, in ar-
resting periodontitis in vivo. Inflammatory alveolar
bone loss was established in rats by local injection
of periopathogenic LPS for 4 weeks, then SD282
was given via oral gavage (along with continued
LPS injections) for an additional 4 weeks. Assessment
of volumetric bone loss, inflammatory cytokine ex-
pression, and osteoclast formation revealed that
SD282 was effective at reducing osteolysis.
Previously, our research group showed that the A.
actinomycetemcomitans LPS injection method is ca-
pable of producing severe alveolar bone loss in rats
within8 weeks.21 Compared to saline-injected controls,
LPS-injected animals exhibited significantly greater
linear bone loss (1.04 versus 0.40 mm cemento-
enamel junction–alveolar bone crest [CEJ-ABC];
P <0.01) and volumetric bone loss (0.37 versus
0.42 BVF; P <0.01). LPS-injected animals also had
significantly increased levels of inflammatory cell
Figure 1.
mCT shows that SD282 limits progression of established LPS-induced alveolar bone loss. Selected three-dimensional isoform displays of rat maxillae
show: (A) normal bone levels in a non-LPS injected animal, (B) interproximal and palatal bone loss after 8 weeks of LPS, (C) interproximal and palatal
bone loss after 4 weeks of LPS followed by 4 weeks of LPS + vehicle, and (D) maintenance of bone after 4 weeks of LPS followed by 4 weeks of
LPS + SD282. Additional isoforms from the LPS-only group at 4 weeks (E) and LPS + SD282 group at 8 weeks (F) allow comparison between
baseline for drug administration and final therapeutic outcome.
Figure 2.
SD282 maintains alveolar bone. Bone volume within an ROI as
assessed by mCT software. Data are presented as fraction of bone
within the ROI (teeth are constant between samples). The difference
between the 8-week LPS (N = 8) and LPS + SD282 (N = 12) groups
was significant (*P <0.001). The difference was P <0.001 for the
LPS + SD282 and 4-week LPS and LPS + vehicle groups.
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infiltrate, inflammatory cytokine (IL-1b and -6 and
TNF-a) expression, and osteoclastogenesis.21
This orally active p38 inhibitor is able to prevent in-
flammatory alveolarbone loss in vivo, asdemonstrated
recently by our laboratory.20 SD282 was administered
concomitantly with LPS injection for 8 weeks. Immuno-
histochemistry results showed that LPS increased
phospho-p38a, whereas SD282 decreased active
p38a (P <0.001). Moreover, SD282 significantly pro-
tected against loss of bone height, area, and volume at
low (15 mg/kg) and high doses (45 mg/kg).
In the current study, changes in bone quantity and
quality were apparent on the physical specimens and
mCT scans. Alterations in bone quality were striking,
with LPS-only specimens exhibiting ‘‘shelled-out’’ or
‘‘Swiss cheese’’ bone. Up to 4 weeks, the resorption
was horizontal; however, after 4 weeks, the bone loss
was mainly within cancellous bone. Hypothetical ex-
planations for this include needle penetration through
the cortical plate, injection into the periodontal liga-
ment space, or a local cytokine-driven process within
the marrow space. This last theory is supported by the
fact that p38 MAPK is required for TNF-a– and IL-1b–
induced RANKL expression in bone marrow stromal
cells.16 Some studies have shown contrasting resorp-
tion patterns between cortical and cancellous bone.
For instance, active vitamin D metabolites act on ma-
ture osteoblasts to increase osteoprotegerin. In mice,
inhibition of these metabolites was less effective in
cancellous bone, rendering it susceptible to resorp-
tion.25 Thus, a volumetric assessment of bone level
seemed most appropriate.
When analyzing the results of this study, it is impor-
tant to remember that the drug was administered in a
model of preexisting active disease. In such a model,
the true baseline is a point at which bone loss or dis-
ease already has been established. Therefore, the
therapeutic goal is to prevent further advancement
of the disease.
Figure 3.
SD282 decreases inflammatory cytokine expression.
Immunohistochemistry (IHC) scores of 0 denote absence of stain,
whereas scores of 4 indicate intense stain and high prevalence of
cytokines. Significant differences in IL-1b (†P <0.01) and TNF-a
(‡P <0.05) were seen between the 8-week LPS + vehicle (N = 11)
and LPS + SD282 (N = 12) groups.
Figure 4.
SD282 inhibits osteoclast formation. Values represent the mean for all
specimens from each group. A statistically significant reduction was
seen between the 8-week LPS and LPS + SD282 groups (†P <0.01).
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This is analogous to a clinical situation where active
periodontitis has resulted in clinically evident alveolar
bone loss. The contemporary concept of periodontal
therapy focuses on eliminating bacteria through me-
chanical means and chemotherapeutics. However,
none of these methods has proven universally effica-
cious, particularly in the case of tissue-invasive spe-
cies such as A. actinomycetemcomitans.26 Moreover,
patients’ compliance with oral hygiene instruction
and maintenance recalls are extremely influential on
treatment outcomes.27 Therefore, the concept of host
modulation has garnered attention in periodontal re-
search. Studies showed significant clinical improve-
ment and reduction of alveolar bone destruction by
modulating arachidonic acid metabolites28,29 and
MMPs.30,31 Successful attempts have been made to
alter osteoclast activity through bisphosphonates32,33
and a novel vacuolar adenosine triphosphatase.34
However, these therapies target singular mechanisms
of alveolar bone destruction.
Conversely, p38 MAPK is an upstream effector
common to many inflammatory cytokines. Activated
monocytes, macrophages, and fibroblasts in the peri-
odontium produce cytokines and prostanoids, includ-
ing TNF-a, IL-1b, and -6, and PGE2.2 These cytokines
induce the production of several inflammatory enzymes
and mediators, such as MMPs, prostaglandins, and
RANKL.35,36 For instance, TNF-a and IL-1 activate
bone marrow stromal cells and macrophages to induce
osteoclastogenesis through RANK–RANKL interac-
tion.37 Inhibition of IL-1 and TNF-a decreases the
spread of inflammatory infiltrate and loss of connective
tissue attachment andalveolar bone.36,38 Because these
cytokines act synergistically, simultaneous blockage of
both is substantially more effective thanblocking one.39
In the first human study,40 a single dose of p38 inhibitor
decreased TNF-a and IL-1 and -6 levels by 90%.
In this study, SD282 had a slight anabolic effect; the
difference between the 8-week LPS-only and LPS +
SD282 groups was significant for increased bone vol-
ume. The reasons for this are unclear, but it may due
to a relatively high suppression of osteoclastogenesis
without compensatory shut-off of osteoblastic differ-
entiation. However, it is not believed that osteoclasto-
genesis is eliminated completely by p38 inhibition.
Systemically, a number of hormones and cytokines
modulate osteoclastogenesis: parathyroid hormone
(PTH); calcitriol; PTH-related protein (PTHrP); PGE2;
and IL-1b, -6, and IL-11.1 Of these, PTH and PTHrP
can activate osteoclastogenesis independent of p38
signaling.41 Conceptually, this makes p38 inhibitor
strategies appealing as a host-modulating agent for
treatment of periodontitis because physiologic bone
turnover (induced by PTH/PTHrP) would occur, but
inflammatory bone loss (induced by LPS, IL-1b, and
TNF-a) would be pharmacologically antagonized.
CONCLUSIONS
Treatment with an orally active p38 MAPK inhibitor
arrested established periodontal disease progression
in vivo. Specifically, SD282 reduced LPS-induced in-
flammatory cytokine expression, osteoclastogenesis,
and alveolar bone loss in rats. Results such as these
support further development of this novel class of
therapeutics and their potential role in treating inflam-
matory diseases, such as periodontitis, in humans.
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